 |
 |
|
|
|
|
 |
|
|
|
|
| Industry Advisors | ||
|
Burton G. Christensen, Ph.D. – Former EVP, Research, Theravance, Inc.; SVP, Chemistry, Merck & Co; inventor of Imipenem, co-inventor of several other antibiotics. Stephen Kaldor, Ph.D. – CEO, Ambrx; former CSO, Takeda, inventor of Viracept. Lynn L. Silver, Ph.D. – LL Silver Consulting. Former Senior Investigator in infectious disease research, Merck and Co. George Miller, Ph.D. – CSO, Blanca Pharmaceuticals; formerly CSO of Microcide; led the development of gentimicin; internationally recognized expert on aminoglycosides. Seemon H. Pines, Ph.D. – Former SVP, Process Chemistry, Merck & Co. Recipient of Chairman's Award for the commercially viable synthesis of imipenem. |
||
| Clinical Advisors | ||
|
William A. Craig, M.D. – University of Wisconsin, Madison Jay Fishman, M.D. – MGH, Harvard Medical School H. Shaw Warren, M.D. – MGH, Harvard Medical School George L. Drusano, M.D. – Ordway Institute, Albany Otto Cars, M.D. – Uppsala University Hospital, Uppsala, Sweden Paul Tulkens, M.D. – Catholic University of Louvain, Brussels, Belgium Vance Fowler, M.D. – Duke University, Duke Clinical Research Institute Henry F. "Chip" Chambers, M.D. – UCSF |
||
| Academic Advisors | ||
|
Peter G. Schultz, Ph.D. – Genomics Institute of the Novartis Foundation Floyd E. Romesberg, Ph.D. – The Scripps Research Institute Matthew Waldor, Ph.D. – Tufts University Stanley Falkow, Ph.D. – Stanford University |
||
| Regulatory Advisors | ||
|
Gino Girardi, M.D. – Former FDA clinical reviewer, anti-infectives division, CDER Hilary Sheevers, Ph.D. – Former FDA drug safety reviewer, anti-infectives division, CDER Bob Osterberg, Ph.D. – Former FDA drug safety reviewer, anti-infectives division, CDER Seemon H. Pines, Ph.D. – Former head of Merck Process Research, worldwide Elizabeth M. Vadas, Ph.D. – Former head of Pharmaceutical R&D, Merck-Frosst |